In vitro stability of three oral vancomycin preparations stored at 2- 5 °C and ambient room temperature for up to 60 days against 100 Clostridioides (Clostridium) difficile and 51Staphylococcus aureus strains

Published on Jun 11, 2018in Anaerobe3.331
· DOI :10.1016/J.ANAEROBE.2018.06.003
Ellie J. C. Goldstein66
Estimated H-index: 66
(UCLA: University of California, Los Angeles),
Diane M. Citron57
Estimated H-index: 57
+ 1 AuthorsEliza S. Leoncio5
Estimated H-index: 5
Sources
Abstract
Abstract Oral vancomycin is used to treat Clostridioides (Clostridium) difficile infection. Several different preparations are available including reconstituted IV solutions, vancomycin capsules, and grape flavored vancomycin oral solution kit (CutisPharma). The shelf life for IV after reconstitution varies between 7 and 14 days under refrigeration, and a standard 30 days for vancomycin oral solution kit (CutisPharma). The impact of storage on the in vitro potency was determined in 3 different vancomycin preparations by measuring MICs for 100 strains of C. difficile and 25 strains of Staphylococcus aureus, at T0, 14, 30, and 60 days, stored at ambient (RT) and refrigerated (2–5 °C) temperatures. All vancomycin preparations showed potency over a period of 60 days regardless of storage conditions. However, the capsule preparation showed mold after 60 days at room temperature, but unlike vancomycin oral solution kit, which retained a clear appearance, the IV and capsule preps showed evidence of crystallization.
📖 Papers frequently viewed together
References8
Newest
Abstract The purpose of this study was to evaluate the stability of two preparations of vancomycin oral solution in two different storage containers, capped amber oral-dosing syringes and heat-sealed oral-dosing cups, stored under refrigerated conditions. Commercially available grape-flavored vancomycin oral preparation and compounded vancomycin for intravenous use in cherry syrup oral preparation were divided into 5-mL aliquots into heat-sealed plastic dosing cups and capped oral-dosing syringe...
#1Paul O. Lewis (Johnson City Medical Center)H-Index: 7
#2Loren Madden Kirk (ETSU: East Tennessee State University)H-Index: 4
Last. Stacy D. Brown (ETSU: East Tennessee State University)H-Index: 12
view all 3 authors...
Purpose Three different generic vancomycin products were compared using liquid chromatography–mass spectrometry (LC-MS) and open-access metabolomic tools. Methods Single-lot samples of vancomycin hydrochloride from three different manufacturers (Hospira, APP Pharmaceuticals, and Pfizer) were reconstituted and injected into a high-resolution LC-MS system. The mass spectral fingerprints were compared for similarity of nonvancomycin B components using the XCMS Online system through Scripps Universi...
Source
#1Stuart Johnson (Loyola University Medical Center)H-Index: 62
#2Thomas J. Louie (U of C: University of Calgary)H-Index: 45
Last. David M. Davidson (Genzyme)H-Index: 5
view all 9 authors...
Background. Clostridium difficile infection (CDI) is a common complication of antibiotic therapy that is treated with antibiotics, contributing to ongoing disruption of the colonic microbiota and CDI recurrence. Two multinational trials were conducted to compare the efficacy of tolevamer, a nonantibiotic, toxin-binding polymer, with vancomycin and metronidazole. Methods. Patients with CDI were randomly assigned in a 2:1:1 ratio to oral tolevamer 9 g (loading dose) followed by 3 g every 8 hours f...
Source
Vancomycin is administered orally for the treatment of pseudomembranous colitis induced by Clostridium difficile. Vancomycin is marketed for this purpose by ViroPharma as VANC o CIN in 125-mg and 250-mg capsules. The need for other dose form options for those patients who cannot take capsules has led compounding pharmacies to seek other alternatives, namely oral solutions and suspensions. Additionally, some patients are unable to use suspending agents containing alcohol or sor bitol. The objecti...
#1Mary H. H. EnsomH-Index: 38
#2Diane DecarieH-Index: 11
Last. Anisha Lakhani (Fraser Health)H-Index: 1
view all 3 authors...
ABSTRACT Background: Solutions of vancomycin for oral administration are not available commercially in Canada or the United States but are needed for patients who cannot swallow capsules. Objective: To evaluate the stability of vancomycin solutions stored in unit-dose cups and plastic bottles under refrigeration (4°C) and at room temperature (25°C) for up to 75 days. Methods: Vancomycin 25 mg/mL in Ora-Sweet vehicle and water (1:1 ratio by volume) was dispensed into opaque blue polyethylene unit...
Source
#1Stuart H. Cohen (UC Davis: University of California, Davis)H-Index: 30
#2Dale N. Gerding (LUC: Loyola University Chicago)H-Index: 105
Last. Mark H. Wilcox (University of Leeds)H-Index: 104
view all 8 authors...
Since publication of the Society for Healthcare Epidemiology of America position paper on Clostridium difficile infection in 1995, significant changes have occurred in the epidemiology and treatment of this infection. C. difficile remains the most important cause of healthcareassociated diarrhea and is increasingly important as a community pathogen. A more virulent strain of C. difficile has been identified and has been responsible for more-severe cases of disease worldwide. Data reporting the d...
Source
#1Fred A. Zar (UIC: University of Illinois at Chicago)H-Index: 6
Last. Melinda B. Davis (UIC: University of Illinois at Chicago)H-Index: 2
view all 4 authors...
Background. The incidence and severity of Clostridium difficile–associated diarrhea (CDAD) has been increasing, and there have been recent reports of metronidazole treatment failure. Metronidazole is still commonly used as first-line treatment for CDAD but has never been compared with vancomycin in a prospective, randomized, double-blind, placebo-controlled trial. We conducted such a trial, stratifying patients according to disease severity, to investigate whether one agent was superior for trea...
Source
#1Mallet LH-Index: 1
#2Sesin GpH-Index: 1
Last. Fraser DgH-Index: 1
view all 4 authors...
Source
Cited By1
Newest
#1Uchini S. Kosgodage (London Metropolitan University)H-Index: 9
#2Paul Matewele (London Metropolitan University)H-Index: 3
Last. Sigrun Lange (University of Westminster)H-Index: 30
view all 11 authors...
Membrane vesicles (MVs) released from bacteria participate in cell communication and host-pathogen interactions. Roles for MVs in antibiotic resistance are gaining increased attention and in this study we investigated if known anti-bacterial effects of cannabidiol (CBD), a phytocannabinoid from Cannabis sativa, could be in part attributed to effects on bacterial MV release. We found that CBD is a strong inhibitor of MV release from Gram-negative bacteria (E. coli VCS257), while inhibitory effect...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.